Back grey_arrow_rt.gif
 
Archived NATAP Articles from May 2003
 
null.gif
 
 
  1. Enfuvirtide, an HIV-1 Fusion Inhibitor - (5/28/03)

    2.  
  2. Switching to Abacavir or Trizivir for Lipodystrophy & Lipids - (5/28/03)

    3.  
  3. Results from the DAD study: Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy - (5/28/03)

    4.  
  4. Extending Treatment for HCV Infection to HIV-HCV Coinfected Individuals with Psychiatric Illness and Drug Dependence - (5/28/03)

    5.  
  5. Prevalence of Hepatitis A, Hepatitis B, and HIV Among Hepatitis C-Seropositive State Hospital Patients: Results From Oregon State Hospital - (5/28/03)

    6.  
  6. DDW - HIV-ASSOCIATED DIARRHEA IN THE ERA OF HAART: STILL PREVALENT AFTER ALL THESE YEARS - (5/28/03)

    7.  
  7. Update on SARS WHO Traces SARS to Civet Cat - (5/27/03)

    8.  
  8. ThGRF in HIV-related lipodystrophy: Phase II clinical trial in Canada and the US - (5/27/03)

    9.  
  9. Fat in the Liver Reduces Response to HCV Therapy - (5/27/03)

    10.  
  10. DDW - Antioxidant-Enhanced Food Found To Reduce Ribavirin-Induced Anemia - (5/27/03)

    11.  
  11. DDW - Preliminary Results from Comparison of PegIntron 1.0 ug/kg vs PegIntron 1.5 ug/kg - (5/27/03)

    12.  
  12. DDW - INTERFERON GAMMA-1B FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTION - (5/27/03)

    13.  
  13. DDW - Pegasys in Children in chronic hepatitis C: safety, efficacy and pharmacokinetics - (5/23/03)

    14.  
  14. DDW - MICRO-NUTRIENTS AND LIVER INJURY IN THE U.S. POPULATION - (5/23/03)

    15.  
  15. DDW - EFFECT OF SILYBUM MARIANUM ON SERUM ALT AND WELL BEING IN CHRONIC HEPATITIS C - (5/23/03)

    16.  
  16. DDW - THE IMPACT OF BODY MASS INDEX (BMI) ON LIVER HISTOLOGY AND TREATMENT TOLERABILITY AND EFFICACY IN CHRONIC HEPATITIS C - (5/23/03)

    17.  
  17. DDW - High Dose Censensus Interferon in Peg-IFN/Ribavirin Nonresponders - (5/22/03)

    18.  
  18. DDW - Retreatment with PegIntron plus Ribavirin for Nonresponders & Relapsers to Prior HCV Therapy - (5/21/03)

    19.  
  19. DDW - Methadone & Pegasys Interactions, Safety and Tolerability - (5/20/03)

    20.  
  20. DDW - RACIAL DIFFERENCES IN RISK FOR LIVER CANCER IN PATIENTS WITH HEPATITIS C CIRRHOSIS: A MULTICENTER CASE-CONTROL STUDY - (5/19/03)

    21.  
  21. DDW - DRAMATIC RISES IN THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN THE UNITED STATES - (5/19/03)

    22.  
  22. DDW - Greetings from Digestive Disease Week 2003: Report 1 - TREATMENT OF HEPATITIS C NON-RESPONDERS - (5/19/03)

    23.  
  23. AIDS Advocates Protest New York City Mayor's Cuts to Housing, Services for People Living With HIV/AIDS - (5/16/03)

    24.  
  24. Retro - Progress in Pharmacology and Drug Interactions From the 10th CROI - (5/16/03)

    25.  
  25. Enfuvirtide (Fuzeon, ENF, T-20), The First HIV Fusion Inhibitor - (5/16/03)

    26.  
  26. Valtrex For Reducing Transmission of Genital Herpes- FDA Hearing: FDA panel votes 11-0 to recommend approval - (5/15/03)

    27.  
  27. FDA Panel Recommends Atazanavir Approval: Report 1 from NATAP - (5/14/03)

    28.  
  28. Atazanavir FDA Hearing, May 13: Report 2 from NATAP - (5/14/03)

    29.  
  29. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens; sexual dysfunction & adherence - (5/12/03)

    30.  
  30. FDA Hearings to Review Atazanavir Protease Inhibitor for HIV & Valtrex For Reduced Herpes Transmission May 13/14 - (5/12/03)

    31.  
  31. CEL-SCI Receives Government Grant to Develop CEL-1000 Against Herpes - (5/9/03)

    32.  
  32. New Surgery for Facial Wasting In HIV Patients - (5/9/03)

    33.  
  33. Occult Hep B: Long-term histologic and virologic outcomes of acute self-limited hepatitis B - (5/9/03)

    34.  
  34. "Syphilis Role in HIV Being Studied in California: STD and HIV Surveillance Working Together" - (5/9/03)

    35.  
  35. Gastrointestinal Tolerability and Pharmacokinetics (blood levels) of the New 625 mg Nelfinavir Tablets - By Jules Levin - (5/7/03)

    36.  
  36. The NEW CDC Prevention Initiative: new strategies for a HIV prevention in 2003 - (5/6/03)

    37.  
  37. Liver Transplantation in HIV-Infected Persons - (5/6/03)

    38.  
  38. Once-a-Day Highly Active Antiretroviral Therapy: A Systematic Review - (5/5/03)

    39.  
  39. Hepatitis C in India - (5/5/03)

    40.  
  40. Research Suggests Viral Failure to Atazanavir Results in Increased Susceptibility to Other Protease Inhibitors - (5/5/03)

    41.  
  41. The HIV Update: Global AIDS Bill; the politics of testing prgnant women for HIV; HIV Superinfection: another case; having sex without disclosing HIV status brings criminal charges; syphilis outbreak in NYC; new HIV test guidelines; non-adherence of HIV drugs continues to be a problem. - (5/5/03)

    42.  
  42. The success of tenofovir (TNF) and didanosine (ddI) when dosed together using low-dose didanosine 250 mg - (5/2/03)

    43.  
  43. Projecting future complications of chronic hepatitis C in the United States - (5/2/03)

    44.  
  44. HCV & HCV/HIV Rates of Fibrosis Progression - (5/2/03)

    45.  
  45. How Often Should Biopsy Be Performed? - (5/2/03)

    46.  
  46. 72 weeks HCV Therapy (PegIFN/RBV): is it effective? - (5/2/03)

    47.